News and Media


The latest from HEMA Biologics

The latest from HEMA Biologics

HEMA Biologics Announces FDA Approval of SEVENFACT® [coagulation factor VIIa (recombinant)-jncw]

HEMA Biologics, LLC, (“HEMA Biologics”) today announced that the U.S. Food and Drug Administration (FDA) approved SEVENFACT® [coagulation factor VIIa (recombinant)-jncw] as the first bypassing agent in over 20 years for adults and adolescents (12 years of age and older) with hemophilia A or B with inhibitors.

Read more

--April 6, 2020--

Archive (Click to expand/hide content)